Please activate JavaScript!
Please install Adobe Flash Player, click here for download
ePaper created 2018-02-16, 11:17:41 | version 1.38.0
manufacturer news zirconia implant solution Nobel Biocare announces entry into metal-free implant market at EAO Hans Geiselhöringer, President Nobel Biocare. Prof. Dr Stefan Holst, Vice President Nobel Biocare. At the 2017 EAO congress, Nobel Biocare has announced that it has entered into a partnership agreement with Dentalpoint, a leader in ceramic dental implants, to add a zirconia implant solution to its portfolio. According to Nobel Biocare President Hans Geiselhöringer, the implant range is “the first truly metal-free, two-piece screw-retained implant solution” and therefore will provide a new option in addition to Nobel Biocare’s leading range of titanium dental implants with the clinically proven TiUnite surface. With 275 million potential edentulous patients around the world, the innova- tions from Dentalpoint, known for its ZERAMEX implant brand, are intended to help clinicians meet the growing demand for metal-free solutions. In further news, Nobel Biocare released the findings of the largest meta- analy sis of a single implant brand to date. It has confirmed the clinical suc- cess of the TiUnite surface, which was launched 17 years ago and has been evaluated in over 465 publications featuring more than 89,500 implants. Karl of Saarland University in Germany and Tomas Albrektsson of the University of Gothenburg in Sweden. They analysed the results of 106 peer-reviewed publications of prospective clinical studies assess- ing implants with the TiUnite surface, including 2,804 implants and 4,694 patients. The results have confirmed that implants with the TiUnite surface have a remarkably low early failure rate and support long-term clinical sur- vival. In the review, early implant and patient level survival rates both exceeded 99 per cent at one year, and the late implant level survival rate was estimated at 95.1 per cent (91.5 per cent at patient level) after ten years. “This meta-analysis unequivocally confirms what extensive internal testing and external validation have documented for over 15 years—that the TiUnite surface supports peri-implant health, bone maintenance and overall success long-term,” said Geiselhöringer. Published in the July/August issue of the International Journal of Oral & Maxillofacial Implants, the review was conducted by Profs. Matthias www.nobelbiocare.com Hans Geiselhöringer, Stefan Holst and Sandro Matter at the EAO press conference (from Nobel Biocare booth at EAO 2017. left to right). 52 CAD/CAM 4 2017